Polyneuron Pharmaceuticals AG

Polyneuron is a pharmaceutical company, committed to the development of a new drug class for the treatment of autoimmune disorders.

Total raised

€32M

€32,375,040

Funding rounds

Investors

distinct backers

Active since

2018-12

latest 2020-09

Funding by year

EUR raised per year

Medium confidence

Raise-next likelihood15

base rate 44% for Series A

Exit likelihood16

base rate 12% (2+ rounds)

Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2020-09-16	Series A	€13M	—	View deal →
2019-01-01	Other	€19M	New Enterprise Associates,Sofinnova Partners	View deal →

same sector or country